CRISPR Therapeutics: Commercial Inflection — Time to Be Selectively Long
CRISPR Therapeutics (CRSP) looks to be at a commercial turning point as Casgevy patient initiations and early sales accelerate. With a $2.33B cash cushion, multiple pipeline readouts ahead and heavy short interest amplifying volatility, this trade idea targets asymmetric upside while protecting capital with a strict stop. Entry $49.75, target $68.0…